Hyderabad: MSN Laboratories Pvt Ltd (MSN) on Friday announced the launch of Posaconazole in India to treat Mucormycosis.
MSN has launched the product under the brand name PosaOne as 100 mg delayed-release tablets and 300 mg injections, respectively. Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients.
Many patients recovering from Covid 19 have been detected with a rare and deadly fungal infection known as mucormycosis or black fungus. With mortality rates on the incline, accessibility of anti-fungal medication is being an unmet deficit in these testing times, the company said.
As an outcome of MSN’s competence in research and manufacturing of antifungal infection drugs, it is now targeting to pro-actively reach patients across India by ensuring the access of PosaOne, through its strong distribution network & field force.
MSN has developed the active pharmaceutical ingredient and the formulation of PosaOne in its in-house R&D and manufacturing units. The drug is approved by the Drug Controller General of India (DGCI) and matches to the International quality standards.
As part of the Covid treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg & 800mg, Oselow (Oseltamivir) as 75 mg capsules and also licensed Baridoz (Baricitinib) recently with Eli Lilly.
